In addition to physical exercise, a number of pharmacological therapies have also been developed with promising potential to improve obesity and type-2 diabetes associated immune dysfunction, such as etanercept (TNF-α blockade) (90). This evidence concerns the gene TNF and obesity due to melanocortin 4 receptor deficiency.